Lead Sponsor

Seung-Jung Park

Collaborators

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

•The patient must be more than or equal to 20 years of age
•Restenosis after drug-eluting stents (\>50% by visual estimate)
•Any Lesion length including focal in stent restenosis or diffuse in stent restenosis
•The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

•The patient has a known hypersensitivity or contraindication to any of the following medications:
•* Heparin
•* Aspirin
•* Both Clopidogrel and TIclopidine
•* Sirolimus eluting stent
•* Stainless steel and/or
•* Contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled)
•Systemic (intravenous) Everolimus use within 12 months.
•Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
•Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
•Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period

Related studies

NCT06075602 · Coronary Disease, Coronary Artery Disease, and more

NCT04475380 · Acute Coronary Syndrome, Angina Pectoris, and more

NCT04494750 · Ischemic Heart Disease, Angina Pectoris, and more

NCT02175706 · Coronary Artery Disease, Angina Pectoris, and more

NCT01759290 · Chronic Total Occlusion of Coronary Artery, Coronary Occlusion, and more

Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis